Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Net Cash Flow: 2009-2024

Historic Net Cash Flow for Ligand Pharmaceuticals (LGND) over the last 16 years, with Dec 2024 value amounting to $50.5 million.

  • Ligand Pharmaceuticals' Net Cash Flow rose 53.63% to $69.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.4 million, marking a year-over-year increase of 71.39%. This contributed to the annual value of $50.5 million for FY2024, which is 329.11% up from last year.
  • Per Ligand Pharmaceuticals' latest filing, its Net Cash Flow stood at $50.5 million for FY2024, which was up 329.11% from -$22.1 million recorded in FY2023.
  • Ligand Pharmaceuticals' 5-year Net Cash Flow high stood at $50.5 million for FY2024, and its period low was -$28.4 million during FY2021.
  • Its 3-year average for Net Cash Flow is $18.0 million, with a median of $25.5 million in 2022.
  • Its Net Cash Flow has fluctuated over the past 5 years, first slumped by 186.53% in 2023, then soared by 329.11% in 2024.
  • Ligand Pharmaceuticals' Net Cash Flow (Yearly) stood at -$24.3 million in 2020, then dropped by 16.98% to -$28.4 million in 2021, then surged by 189.61% to $25.5 million in 2022, then slumped by 186.53% to -$22.1 million in 2023, then soared by 329.11% to $50.5 million in 2024.